The European patient with Dravet syndrome: Results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome

Epilepsy and Behavior

Volumn 44, Issue , 2015, Pages 104-109

  Aras, Luis Miguel ^a   Isla, Julián ^a   Mingorance Le Meur, Ana ^a  

^a Dravet Syndrome Foundation Spain   (Spain)

Author keywords

Antiepileptic drug; Childhood epilepsy; Clinical trials; Dravet syndrome; Orphan drug; Stiripentol

Indexed keywords

ANTICONVULSIVE AGENT; CLOBAZAM; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL NAV1.1; STIRIPENTOL; VALPROIC ACID; 1,3 DIOXOLANE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; SCN1A PROTEIN, HUMAN;

ADOLESCENT; ARTICLE; CHILD; COMORBIDITY; EUROPEAN; FEMALE; GENE MUTATION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; TONIC CLONIC SEIZURE; EPILEPSIES, MYOCLONIC; EUROPE; GENETICS; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ANTICONVULSANTS; BENZODIAZEPINES; CHILD; CHILD, PRESCHOOL; DIOXOLANES; EPILEPSIES, MYOCLONIC; EUROPE; FEMALE; HUMANS; MALE; NAV1.1 VOLTAGE-GATED SODIUM CHANNEL; SODIUM CHANNEL BLOCKERS; VALPROIC ACID;

EID: 84922379236     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2014.12.028     Document Type: Article

References (28)

1. Dravet C. The core Dravet syndrome phenotype. Epilepsia 2011, 52(Suppl. 2):3-9.
2. Dravet C. Terminology and prognosis of Dravet syndrome. Epilepsia 2014, 55(6):942-943.
3. Scheffer I.E. Diagnosis and long-term course of Dravet syndrome. Eur J Paediatr Neurol 2012, 16(Suppl. 1):S5-S8.
4. Marini C., Scheffer I.E., Nabbout R., Suls A., De Jonghe P., Zara F., et al. The genetics of Dravet syndrome. Epilepsia 2011, 52(Suppl. 2):24-29.
5. Lemke J.R., Riesch E., Scheurenbrand T., Schubach M., Wilhelm C., Steiner I., et al. Targeted next generation sequencing as a diagnostic tool in epileptic disorders. Epilepsia 2012, 53(8):1387-1398.
6. Claes L., Del-Favero J., Ceulemans B., Lagae L., Van Broeckhoven C., De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001, 68(6):1327-1332.
7. Claes L., Ceulemans B., Audenaert D., Smets K., Löfgren A., Del-Favero J., et al. De novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy. Hum Mutat 2003, 21(6):615-621.
8. Goldberg-Stern H., Aharoni S., Afawi Z., Bennett O., Appenzeller S., Pendziwiat M., et al. Broad phenotypic heterogeneity due to a novel SCN1A mutation in a family with genetic epilepsy with febrile seizures plus. J Child Neurol 2014, 29(2):221-226.
9. O'Roak B.J., Vives L., Girirajan S., Karakoc E., Krumm N., Coe B.P., et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 2012, 485(7397):246-250.
10. Frosk P., Mhanni A.A., Rafay M.F. SCN1A mutation associated with intractable myoclonic epilepsy and migraine headache. J Child Neurol 2013, 28(3):389-391.
11. Patino G.A., Claes L.R., Lopez-Santiago L.F., Slat E.A., Dondeti R.S., Chen C., et al. A functional null mutation of SCN1B in a patient with Dravet syndrome. J Neurosci 2009, 29(34):10764-10778.
12. Shi X., Yasumoto S., Nakagawa E., Fukasawa T., Uchiya S., Hirose S. Missense mutation of the sodium channel gene SCN2A causes Dravet syndrome. Brain Dev 2009, 31(10):758-762.
13. A receptors in severe epilepsy. Epilepsy Res 2014, 108(3):420-432.
14. Suls A., Jaehn J.A., Kecskés A., Weber Y., Weckhuysen S., Craiu D.C., et al. De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome. Am J Hum Genet 2013, 93(5):967-975.
15. Depienne C., Bouteiller D., Keren B., Cheuret E., Poirier K., Trouillard O., et al. Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females. PLoS Genet 2009, 5(2):e1000381.
16. Stenhouse S.A., Ellis R., Zuberi S. SCN1A genetic test for Dravet syndrome (severe myoclonic epilepsy of infancy and its clinical subtypes) for use in the diagnosis, prognosis, treatment and management of Dravet syndrome. PLoS Curr 2013, 5.
17. Chiron C., Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia 2011, 52(Suppl. 2):72-75.
18. Chiron C., Marchand M.C., Tran A., Rey E., d'Athis P., Vincent J., et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000, 356(9242):1638-1642.
19. Chiron C. Stiripentol. Neurotherapeutics 2007, 4(1):123-125.
20. Brunklaus A., Ellis R., Reavey E., Forbes G.H., Zuberi S.M. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain 2012, 135(Pt 8):2329-2336.
21. Nabbout R., Chemaly N., Chipaux M., Barcia G., Bouis C., Dubouch C., et al. Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis 2013, 8:176.
22. Ragona F., Granata T., Dalla Bernardina B., Offredi F., Darra F., Battaglia D., et al. Cognitive development in Dravet syndrome: a retrospective, multicenter study of 26 patients. Epilepsia 2011, 52(2):386-392.
23. Orosz I., McCormick D., Zamponi N., Varadkar S., Feucht M., Parain D., et al. Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24months in 347 children. Epilepsia 2014, 55(10):1576-1584.
24. McTague A., Cross J.H. Treatment of epileptic encephalopathies. CNS Drugs 2013, 27(3):175-184.
25. Laux L., Blackford R. The ketogenic diet in Dravet syndrome. J Child Neurol 2013, 28(8):1041-1044.
26. Striano P., Coppola A., Pezzella M., Ciampa C., Specchio N., Ragona T., et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007, 69(3):250-254.
27. Chiron C. Current therapeutic procedures in Dravet syndrome. Dev Med Child Neurol 2011, 53(Suppl. 2):16-18.
28. Guerrini R., Belmonte A., Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998, 39(Suppl. 3):S2-S10.